Panobinostat is an oral pan-histone deacetylase inhibitor developed by Novartis. Panobinostat acts via epigenetic modification and inhibition of the aggresome pathway.
This article summarizes the scientific review of the application leading to regulatory approval in the European Union.
Novartis announced that the European Commission has approved Farydak (panobinostat, previously known as LBH589) capsules, in combination with bortezomib and...
Novartis has presented results from a pivotal Phase III clinical trial exploratory subgroup analysis showing a 7.8-month improvement in median...
Novartis announced that the FDA has approved Farydak (panobinostat, previously known as LBH 589) capsules in combination with bortezomib and...
The National Institute for Health and Care Excellence (NICE) in a final appraisal now recommends Farydak + Velcade (panobinostat +...
Farydak, in combination with bortezomib and dexamethasone, is indicated for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent.
Novartis presented results from a pivotal Phase III trial showing a 37% improvement in progression-free survival (PFS) when using the...
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for...